• 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚 (𝗔𝗳𝗼𝘅𝗼𝗹𝗮𝗻𝗲𝗿 + 𝗠𝗶𝗹𝗯𝗲𝗺𝘆𝗰𝗶𝗻 𝗢𝘅𝗶𝗺𝗲): 𝗔 𝗖𝗼𝗺𝗯𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗔𝗻𝘁𝗶𝗽𝗮𝗿𝗮𝘀𝗶𝘁𝗶𝗰 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲
SPECTRA FOR DOGS 2–3.5 KG is a veterinary antiparasitic chewable tablet containing afoxolaner and milbemycin oxime. The 2–3.5 kg presentation contains approximately 9.375 mg of afoxolaner and 1.875 mg of milbemycin oxime per tablet. It is designed for dogs within the specified body-weight range and provides activity against important external and internal parasites.
Afoxolaner is an ectoparasiticide belonging to the isoxazoline class and is active against fleas and ticks. Milbemycin oxime is a macrocyclic lactone used against susceptible nematode parasites and contributes to heartworm prevention when administered according to the approved veterinary regimen. The product should be selected according to the dog's actual body weight and used under veterinary guidance, particularly in puppies, breeding animals, or dogs with existing medical conditions.
• 𝗞𝗲𝘆 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚
1. Helps control flea infestations in dogs within the appropriate weight range.
2. Provides activity against several clinically important tick species.
3. Helps treat susceptible gastrointestinal nematode infestations.
4. Milbemycin oxime provides prevention of heartworm disease when used according to the veterinary dosing schedule.
5. Combines external and internal parasite control in a convenient chewable formulation.
• 𝗛𝗼𝘄 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚 𝗪𝗼𝗿𝗸𝘀
Afoxolaner selectively interferes with ligand-gated chloride channels in arthropods, particularly GABA-gated and glutamate-gated chloride channels, disrupting normal neuronal transmission and resulting in paralysis and death of susceptible fleas and ticks. Milbemycin oxime binds to glutamate-gated chloride channels in susceptible nematodes, increasing chloride-ion permeability and causing neuromuscular paralysis. The combined pharmacological activity provides complementary control of susceptible external and internal parasites.
• 𝗨𝘀𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚
1. Dosage: The 2–3.5 kg presentation is intended for dogs weighing within this specified range; dosing should follow the approved product label and veterinarian's instructions.
2. Administration: Administer orally as a chewable tablet. Do not substitute a different strength without confirming the appropriate weight-based product.
3. Timing: The product is generally administered at monthly intervals for indications requiring repeated treatment or prevention, according to the approved veterinary regimen.
4. Monitoring: Veterinary monitoring may be appropriate for puppies, dogs with parasite infections, dogs receiving prolonged preventive treatment, or animals with relevant medical conditions.
5. Precautions: Weigh the dog accurately before administration and seek veterinary advice if the dog is very young, pregnant, lactating, debilitated, or has a history of seizures.
• 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝘁𝗮𝗴𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚
1. Afoxolaner provides systemic activity against susceptible fleas and ticks following oral administration.
2. Milbemycin oxime provides activity against susceptible gastrointestinal nematodes.
3. The combination can provide broader parasite coverage than an agent directed at only one parasite group.
4. Regular administration according to the approved regimen can help maintain ongoing parasite prevention.
5. The weight-specific formulation helps support accurate dosing in small dogs when the correct presentation is selected.
• 𝗢𝗳𝗳-𝗟𝗮𝗯𝗲𝗹 𝗨𝘀𝗲𝘀 𝗼𝗳 𝗦𝗣𝗘𝗖𝗧𝗥𝗔 𝗙𝗢𝗥 𝗗𝗢𝗚𝗦 𝟮–𝟯.𝟱 𝗞𝗚
Off-label use means administering a veterinary medicine in a manner that differs from its approved label, such as for a different parasite, indication, dosage regimen, or animal population. Such use should only be considered by a veterinarian after evaluating the individual animal.
1. A veterinarian may consider alternative treatment regimens for certain susceptible parasitic conditions when supported by clinical judgment and available evidence.
2. Veterinary professionals may sometimes use an approved active ingredient for a parasite or clinical circumstance not specifically included on the local product label.
3. A veterinarian may determine an alternative administration strategy when standard labelled options are unsuitable for an individual dog.
• 𝗘𝘅𝗽𝗲𝗿𝘁 𝗔𝗱𝘃𝗶𝗰𝗲 𝗳𝗼𝗿 𝗢𝗽𝘁𝗶𝗺𝗮𝗹 𝗨𝘀𝗲
1. Confirm the dog's current body weight before selecting the tablet strength.
2. Follow the veterinarian's recommended dosing interval consistently.
3. Do not use a larger-strength tablet simply because the dog is close to the upper weight limit.
4. Tell the veterinarian about previous seizures, neurological disorders, pregnancy, lactation, or other medicines being used.
5. Heartworm prevention should be maintained according to the veterinary schedule appropriate for the dog's geographic and clinical risk.
6. Seek veterinary attention if vomiting, diarrhea, marked lethargy, neurological signs, or another unexpected reaction occurs after treatment.
• 𝗦𝘁𝗼𝗿𝗮𝗴𝗲 𝗜𝗻𝘀𝘁𝗿𝘂𝗰𝘁𝗶𝗼𝗻𝘀
1. Store the product according to the manufacturer's labelled storage conditions.
2. Keep tablets in their original packaging until administration.
3. Protect the medicine from excessive heat, moisture, and direct sunlight.
4. Keep out of reach of children and animals for which the medicine was not prescribed.
5. Do not use tablets after the expiry date or if the packaging is damaged.
• 𝗙𝗿𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆 𝗔𝘀𝗸𝗲𝗱 𝗤𝘂𝗲𝘀𝘁𝗶𝗼𝗻𝘀 (𝗙𝗔𝗤𝘀)
• Q: What is SPECTRA FOR DOGS 2–3.5 KG?
A: SPECTRA FOR DOGS 2–3.5 KG is a veterinary antiparasitic chewable tablet containing afoxolaner and milbemycin oxime for dogs in the specified body-weight range.
• Q: What are the active ingredients in SPECTRA FOR DOGS 2–3.5 KG?
A: Each tablet contains approximately 9.375 mg of afoxolaner and 1.875 mg of milbemycin oxime.
• Q: What parasites does SPECTRA FOR DOGS help control?
A: Depending on the approved indication, it provides activity against fleas, ticks, susceptible gastrointestinal nematodes, and contributes to heartworm prevention.
• Q: How often is SPECTRA FOR DOGS administered?
A: For indications requiring continued protection, it is generally administered once every month according to the approved veterinary regimen.
• Q: Can SPECTRA FOR DOGS be used for puppies?
A: Eligibility depends on the puppy's age, body weight, health status, and the local product label. A veterinarian should confirm whether treatment is appropriate.
• Q: Can SPECTRA FOR DOGS be used in dogs with seizures?
A: Dogs with a history of seizures or neurological disorders should be evaluated by a veterinarian before receiving an isoxazoline-containing product because neurological adverse reactions have been reported.
• Q: Is SPECTRA FOR DOGS available without a prescription?
A: Regulatory status varies by country. Some jurisdictions classify the product as prescription-only, so customers should follow local veterinary and dispensing requirements.
